Roche reported that its oral selective estrogen receptor degrader (SERD) missed the primary endpoint in a Phase 3 first‑line breast cancer trial. The drug, giredestrant, had shown promise in adjuvant and later‑line settings but failed to demonstrate the expected benefit in treatment‑naïve patients. The negative readout calls into question whether the oral SERD mechanism can deliver broad first‑line efficacy and will force Roche to reassess development plans and regulatory positioning. Clinical details indicate the compound’s earlier signals did not translate to this larger, frontline population. Analysts and competitors will parse subgroup and biomarker data to determine whether any patient subsets remain viable for follow‑up.